Of note, we observed higher NF-κB activation in cisplatin resistant cells (both ES2C and A2780C cells), as compared to the respective parental cells (ES2 and A2780 cells), which is in agreement with earlier reports of increased NF-κB signaling in cisplatin resistance ovarian cancer cells. Here, NFKB1 is linked to ovarian carcinoma.